Vir Biotechnology (VIR) Long-Term Investments (2018 - 2026)

Vir Biotechnology has disclosed Long-Term Investments across 9 years of filings, most recently posting $333.0 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $333.0 million, up 52.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $333.0 million (up 52.64% YoY), and the FY2025 annual result was $314.6 million, up 65.55% from the prior year.
• Long-Term Investments came in at $333.0 million for Q1 2026 at Vir Biotechnology, up from $314.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $359.7 million in Q1 2024 to a low of $23.9 million in Q4 2022.
• The 5-year median for Long-Term Investments is $190.0 million (2024), against an average of $180.2 million.
• Peak annual rise in Long-Term Investments reached 1612.02% in 2022, while the deepest fall reached 88.12% in 2022.
• Vir Biotechnology's Long-Term Investments stood at $23.9 million in 2022, then surged by 339.98% to $105.3 million in 2023, then soared by 80.49% to $190.0 million in 2024, then surged by 65.55% to $314.6 million in 2025, then rose by 5.85% to $333.0 million in 2026.
• The last three Long-Term Investments figures came in at $333.0 million (Q1 2026), $314.6 million (Q4 2025), and $304.2 million (Q3 2025), per Business Quant data.